BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 32365599)

  • 1. Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies.
    Coccaro N; Tota G; Anelli L; Zagaria A; Specchia G; Albano F
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
    Della Starza I; De Novi LA; Santoro A; Salemi D; Tam W; Cavalli M; Menale L; Soscia R; Apicella V; Ilari C; Vitale A; Testi AM; Inghirami G; Chiaretti S; Foà R; Guarini A
    Leuk Lymphoma; 2019 Nov; 60(11):2838-2840. PubMed ID: 31050551
    [No Abstract]   [Full Text] [Related]  

  • 3. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
    Sánchez R; Ayala R; Martínez-López J
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of allele-specific quantitative PCR using genomic DNA to monitor minimal residual disease based on mutant gene levels following allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies: comparison of mutant levels with autologous DNA percentage by short tandem repeat-PCR.
    Taira C; Matsuda K; Saito S; Sakashita K; Sugano M; Okumura N; Honda T
    Clin Chim Acta; 2012 Feb; 413(3-4):516-9. PubMed ID: 22138486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
    Wolf J; Fonseca R; Muffly L
    Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods of minimal residual disease (MRD) detection in childhood haematological malignancies.
    Jółkowska J; Derwich K; Dawidowska M
    J Appl Genet; 2007; 48(1):77-83. PubMed ID: 17272865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of next-generation sequencing in hematologic malignancies.
    Ramkissoon LA; Montgomery ND
    Hum Immunol; 2021 Nov; 82(11):859-870. PubMed ID: 33648805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular detection of minimal residual disease in multiple myeloma.
    Bai Y; Orfao A; Chim CS
    Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.
    Mansier O; Migeon M; Saint-Lézer A; James C; Verger E; Robin M; Socié G; Bidet A; Mahon FX; Cassinat B; Lippert E
    J Mol Diagn; 2016 Jan; 18(1):68-74. PubMed ID: 26596525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing.
    Denis JA; Guillerm E; Coulet F; Larsen AK; Lacorte JM
    Mol Diagn Ther; 2017 Dec; 21(6):587-600. PubMed ID: 28667577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
    Cilloni D; Petiti J; Rosso V; Andreani G; Dragani M; Fava C; Saglio G
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
    Shapiro RM; Kim DDH
    Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. dPCR application in liquid biopsies: divide and conquer.
    Moreno-Manuel A; Calabuig-Fariñas S; Obrador-Hevia A; Blasco A; Fernández-Díaz A; Sirera R; Camps C; Jantus-Lewintre E
    Expert Rev Mol Diagn; 2021 Jan; 21(1):3-15. PubMed ID: 33305634
    [No Abstract]   [Full Text] [Related]  

  • 16. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.
    Lamy PJ; Castan F; Lozano N; Montélion C; Audran P; Bibeau F; Roques S; Montels F; Laberenne AC
    J Mol Diagn; 2015 Jul; 17(4):366-73. PubMed ID: 25952101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCR for monitoring of minimal residual disease in hematologic malignancy.
    Matsuda K; Sugano M; Honda T
    Clin Chim Acta; 2012 Jan; 413(1-2):74-80. PubMed ID: 22057038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course.
    Taira C; Matsuda K; Kamijyo Y; Sakashita K; Ishida F; Kumagai T; Yamauchi K; Okumura N; Honda T
    Clin Chim Acta; 2011 Jan; 412(1-2):53-8. PubMed ID: 20849840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
    Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
    Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR.
    Starza ID; Eckert C; Drandi D; Cazzaniga G;
    Methods Mol Biol; 2022; 2453():79-89. PubMed ID: 35622321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.